Serum Bactericidal Activity of Three Different Dosing Regimens of Colistin with Implications for Optimum Clinical Use
- 1 June 2010
- journal article
- Published by Taylor & Francis Ltd in Journal of Chemotherapy
- Vol. 22 (3), 175-178
- https://doi.org/10.1179/joc.2010.22.3.175
Abstract
Although colistin methanesulfonate (CMS) has been used extensively in critically ill patients infected with multidrug-resistant organisms, the optimum dosing regimen remains to be determined. Herein, we examined the pharmacokinetics of three different dosing regimens of CMS, 3 million units every 8 h (regimen A), 4.5 million units every 12 h (regimen B), 9 million units every 24 h (regimen C) and evaluated the bactericidal activity of serum containing various concentrations of colistin against Pseudomonas aeruginosa with a minimum inhibitory concentration (MIC) of 1 microg/ml. the means +/- SE serum C(max )of colistin for regimens A, B, and C were 3.34+/-0.35, 2.98+/-0.27, and 5.63+/-0.87 microg/ml, respectively. All serum samples containing colistin >4 microg/ml (serum concentration/MIC >4) eliminated P. aeruginosa whereas only 40% of samples containing colistin <4 microg/ml resulted in complete bacterial killing. these findings indicate that the currently used dosing regimens might not provide the most effective therapy with CMS and justify administering larger dosages in longer intervals.Keywords
This publication has 9 references indexed in Scilit:
- Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative BacilliAntimicrobial Agents and Chemotherapy, 2008
- Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic modelJournal of Antimicrobial Chemotherapy, 2008
- Colistin Methanesulfonate against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2007
- Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsThe Lancet Infectious Diseases, 2006
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005
- Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High-Performance Liquid ChromatographyAntimicrobial Agents and Chemotherapy, 2002
- A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2001
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998